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Summary
BACKGROUND: Despite a low positive predictive value,
diagnostic tests such as complete blood count (CBC) and
C-reactive protein (CRP) are commonly used to evaluate
whether infants with risk factors for early-onset neonatal
sepsis (EOS) should be treated with antibiotics.
STUDY DESIGN: We investigated the impact of imple-
menting a protocol aiming at reducing the number of dia-
gnostic tests in infants with risk factors for EOS in order
to compare the diagnostic performance of repeated clinical
examination with CBC and CRP measurement. The
primary outcome was the time between birth and the first
dose of antibiotics in infants treated for suspected EOS.
RESULTS: Among the 11,503 infants born at ≥35 weeks
during the study period, 222 were treated with antibiotics
for suspected EOS. The proportion of infants receiving an-
tibiotics for suspected EOS was 2.1% and 1.7% before and
after the change of protocol (p = 0.09). Reduction of dia-
gnostic tests was associated with earlier antibiotic treat-
ment in infants treated for suspected EOS (hazard ratio
1.58; 95% confidence interval [CI] 1.20–2.07; p <0.001),
and in infants with neonatal infection (hazard ratio 2.20;
95% CI 1.19–4.06; p = 0.01). There was no difference in
the duration of hospital stay nor in the proportion of infants
requiring respiratory or cardiovascular support before and
after the change of protocol.
CONCLUSION: Reduction of diagnostic tests such as
CBC and CRP does not delay initiation of antibiotic treat-
ment in infants with suspected EOS. The importance of
clinical examination in infants with risk factors for EOS
should be emphasised.
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Introduction
Early-onset neonatal sepsis (EOS) is associated with high
mortality and morbidity [1, 2]. In consequence, antibiotics
are started promptly in infants with clinical signs suggest-
ive of bacterial infection. In asymptomatic newborns with
risk factors for EOS (mother inadequately treated for col-
onisation with Group B Streptococcus (GBS), maternal
fever, prolonged rupture of membranes, and prematurity),
a complete blood count (CBC) and measurement of acute
phase reactants are commonly used to decide whether an-
tibiotics should be administered [3–5]. However, the low
positive predictive value of these diagnostic tests results in
administration of antibiotics to a large number of infants
in whom the diagnosis of EOS will be ruled out 48–72
hours later owing to negative blood cultures, rapid clinical
improvement and normalisation of diagnostic tests [6–11].
Moreover, the vast majority of infants who develop EOS
become symptomatic within the first 24 hours of life [7, 8,
12, 13]. Therefore, we hypothesised that evaluating infants
with risk factors for EOS by repeated clinical examination
without using diagnostic blood tests does not delay initi-
ation of antibiotics treatment. To compare the performance
of repeated clinical examination with CBC and C-reactive
protein (CRP) measurement, we investigated the impact of
reducing diagnostic tests on the timing of initiation of anti-
biotic treatment in infants with suspected EOS.
Patients and methods
Patients and data collection
This historically controlled study was approved by the In-
stitutional Review Boards of the University of Lausanne.
Infants were included if they were born at the Lausanne
University Hospital between December 2006 and Decem-
ber 2011 at a gestational age ≥35 weeks and received intra-
venous antibiotics during the first week of life for suspec-
ted EOS. Newborns with severe congenital malformations
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and infants receiving antibiotics as prophylaxis were ex-
cluded. During the whole study period, intrapartum anti-
biotic prophylaxis was administered to mothers colonised
with GBS as recommended by Centers for Disease Control
and Prevention [14].
Two time periods were compared, before and after the
change of our screening protocol for infants born with risk
factors for EOS:
Period 1, December 2006 – September 2009: A CBC with
manual differential count and a measurement of CRP were
performed in all infants born to mothers with at least one
risk factor for neonatal infection (inadequate GBS prophy-
laxis, rupture of membranes >18 hours [PROM], maternal
fever, prematurity <37 weeks of gestation), in accordance
with the 2002 guidelines of the Swiss Society of Neonato-
logy [3]. No specific instructions were given to clinicians
regarding the timing of diagnostic tests. Vital signs were
checked by midwives every 4 hours during the first 24
hours and every 8 hours during the next 24 hours in all in-
fants with risk factors for EOS.
Period 2, October 2009 – December 2011: In addition to
the monitoring of vital signs by midwives, infants with
risk factors for EOS were examined by paediatric residents
every 8 hours during the first 24 hours. A CBC was per-
formed only in infants exposed to maternal chorioamnion-
itis, defined as maternal fever >38 °C plus at least two of
the following signs: maternal heart rate >100/min, foetal
heart rate >160/min, uterine tenderness, purulent amniotic
fluid, maternal leucocytosis 15,000/mm3. During the two
study periods, the decision to start antibiotics was at the
discretion of the attending neonatologist and blood cultures
were obtained only in treated patients. Blood cultures,
CBCs and CRP measurements were performed during the
two study periods in all treated patients to assist clinicians
in determining the duration of antibiotic treatment. Lumbar
punctures were performed on an individual basis and urine
cultures were not part of the diagnostic workup for EOS
[15].
Infants treated with antibiotics for suspected EOS during
Period 1 and Period 2 were identified using the clinical
information system MetaVision (iMDsoft, Massachusetts,
USA) and our neonatal database. During Period 2, cases
were also collected prospectively by the reporting of each
infant treated with antibiotics during the first week of life.
Prospective collection of cases during Period 2 showed that
MetaVision effectively identified all infants treated with
antibiotics for suspected EOS (no cases were missed).
Outcomes
Neonatal infection was defined as: (A) culture-proven in-
fection (positive blood and/or cerebrospinal fluid culture)
or (B) probable infection with ≥2 signs of sepsis within
the first 7 days of life (temperature instability, irritability
or lethargy, feeding difficulties, capillary refill >2 seconds,
apnoea, tachycardia and/or tachypnoea), and elevated CRP
>20 mg/l, and the decision of the attending neonatologist to
treat for at least 7 days with intravenous antibiotics. Nonin-
fected neonates were those who did not meet the above cri-
teria. The primary outcome measure was the time between
birth and the first dose of antibiotics in infants treated for
suspected EOS. Secondary outcomes were the duration of
the antibiotics treatment, the duration of hospital stay, and
the occurrence of complications defined as requirement
for catecholamine treatment, mechanical ventilation, men-
ingitis or death. A composite variable for the occurrence
of any of the above mentioned complications was also cre-
ated.
Statistical analyses
Baseline clinical characteristics were described by showing
the median and the first and third quartiles (Q1–Q3) for
continuous variables, and numbers and percentages for cat-
egorical variables. Comparisons of continuous and categor-
ical variables between the patients from Period 1 and Peri-
od 2 were performed using two-tailed t-tests and Pearson's
Chi-squared tests (with Yates’ continuity correction when
required).
Survival curves were estimated using the Kaplan-Meier
method. Cox regression model was fitted to study the effect
of the study period on the time between birth and initiation
of antibiotics. Results were expressed as hazard ratios
(HRs) with their 95% confidence interval (95% CI). The
level of significance was set at 0.05. Univariable analysis
was performed in all treated patients, and in the subgroups
of patients with or without neonatal infection. Multivari-
able analysis adjusted the effect of the time period for po-
tential confounding covariables that were chosen a priori
(gestational age, birthweight, gender, PROM, maternal col-
onisation with GBS, caesarean section). Only the covari-
ables that showed a univariable association at the 0.10 level
with the time between birth and the first dose of antibiotics
were included in the final model. Statistical analyses were
performed on the R-software version 2.14.1 (R Develop-
ment Core Team, Vienna, Austria).
Results
During the whole study period, 11,613 infants were born at
our institution at a gestational age ≥35 weeks. Fifty-five in-
fants born during Period 1 and fifty-five infants born dur-
ing Period 2 were excluded from the study owing to severe
congenital malformations or treatment with prophylactic
antibiotics. Clinical characteristics of the remaining infants
born during Period 1 (n = 6183) and their mothers were
similar to those of the infants born during Period 2 (n =
5,320, data not shown). Among these 11,503 infants, 222
were treated with antibiotics for suspected EOS, and there-
Figure 1
Kaplan-Meier estimates of the time between birth and the first dose
of antibiotics in: (A) all infants treated for suspected early-onset
neonatal sepsis during Period 1 (full line, n = 132) and Period 2
(dotted line, n = 90), p <0.001; (B) infants with neonatal infection
during Period 1 (full line, n = 36) and Period 2 (dotted line, n = 16),
p <0.001.
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fore met our inclusion criteria. The proportion of infants
born at a gestational age ≥35 weeks who received antibiot-
ics for suspected EOS was 2.1% (132/6,183) during Period
1 and 1.7% (90/5,320) during Period 2 (p = 0.09).
Baseline characteristics of the included patients were sim-
ilar in the two study periods (table 1). Neonatal infection
(as defined in “Patients and methods”) occurred in 27.3%
(36/132) of the treated patients during Period 1, and 17.8%
(16/90) of the treated patients during Period 2 (p = 0.10,
table 2). Three patients from Period 1 had positive blood
cultures growing Escherichia coli, Streptococcus pneumo-
niae and Streptococcus mitis. One patient from Period 1
had meningitis diagnosed by cerebrospinal fluid pleocytos-
is on two successive lumbar punctures. None of the patients
from Period 2 had positive blood or cerebrospinal fluid cul-
tures. EOS was ruled out in 72.7% (96/132) and 82.2% (74/
90) of the patients treated with antibiotics during Period 1
and Period 2, respectively (p = 0.10). Therefore, one could
estimate that the rate of unnecessary antibiotic treatments
in infants born at a gestational age ≥35 weeks was 1.6%
(96/6183) during Period 1 and 1.4% (74/5320) during Peri-
od 2 (p = 0.47).
Time between birth and the first dose of antibiotics was
shorter during Period 2 (median 4.5 hours; Q1–Q3
2.6–10.9 hours) compared with Period 1 (median 10.7
hours; Q1–Q3 4.1–26.9 hours; table 2). Duration of anti-
biotic treatment was shorter during Period 2 (median 64.2
hours; Q1–Q3 62.3–133.3) compared with Period 1 (medi-
an 77.5 hours; Q1–Q3 64.0–158.3, p = 0.001) in all treated
patients, and in noninfected patients (median 66.6 hours;
Q1–Q3 62.4–127.1 during Period 1 and 64.0 hours; Q1–Q3
60.6–66.8 during Period 2, p = 0.003), but not in patients
with neonatal infection (median 165.6 hours; Q1–Q3
153.8–233.0 during Period 1 and 160.4 hours; Q1–Q3
153.4–163.9 during Period 2, p = 0.38). The duration of
hospital stay and the proportion of patients that required
noninvasive and/or invasive ventilation and/or catecholam-
ine treatment were similar during the two study periods for
all treated patients and for patients with neonatal infection
(table 2 and data not shown). One patient died during Peri-
od 1 from severe perinatal asphyxia, and no patient died
during Period 2.
Survival analysis verified that infants who received antibi-
otics for suspected EOS were treated earlier during Peri-
od 2 than during Period 1 (HR 1.58; 95% CI, 1.20–2.07; p
<0.001, fig. 1A). The difference between the two periods
was even more marked in the subgroup of patients with
neonatal infection (HR 2.20; 95% CI, 1.19–4.06; p = 0.01,
fig. 1B). There was also a significant, but less marked, dif-
ference in the timing of initiation of antibiotic treatment
in the subgroup of noninfected patients (HR 1.38; 95%
CI, 1.02–1.87; p = 0.04). In univariable analysis performed
on all treated patients, antibiotics were started earlier in
patients with a lower gestational age and birthweight (p
<0.05, table 3). A trend towards a correlation between
PROM and the timing of antibiotic treatment was observed
(p = 0.065), whereas no such association was found for
the other tested covariables (gender, maternal colonisation
with GBS and mode of delivery). Multivariable analysis
adjusted for birthweight, gestational age and PROM con-
firmed the earlier initiation of antibiotic treatment during
Period 2 compared with Period 1 (HR 1.56; 95% CI,
1.17–2.07; p = 0.002, table 3).
The proportion of patients who had clinical signs suggest-
ing EOS when the decision was made to start antibiotics
was 96.2% (127/132) during Period 1 and 97.8% (88/90)
during Period 2 (p = 0.79). The number of CRP measure-
mentss and CBCs performed at our maternity clinic was
26.8 and 51.3 per 100 live births during Period 1 and 2.3
and 36.1 per 100 live births during Period 2 (p <0.0001).
CBCs and CRP measurements were performed in all pa-
tients who received antibiotics during Period 1 at a median
postnatal age of 2.4 hours (Q1–Q3 1.3–7.6). During Peri-
od 2, CBCs and CRP levels were obtained prior to the start
of antibiotics in 8/90 patients that received antibiotics, at a
median postnatal age of 7.0 hours (Q1–Q3 4.6–12.0). Ex-
cluding these 8 patients from analysis lead to a median time
between birth and the first dose of antibiotics of 4.2 hours
(Q1–Q3 2.5–8.0) during Period 2, which is shorter than in
Period 1 (p <0.001).
Discussion
Reduction in the use of diagnostic tests in term and late-
preterm infants with risk factors for EOS did not delay the
initiation of antibiotic treatment. On the contrary, it resul-
ted in earlier treatment in all the patients treated for in-
fection and in the subgroups of patients with and without
neonatal infection. Indeed, after the introduction of a pro-
tocol that limited the number of diagnostic tests and im-
Table 1: Baseline characteristics of the newborn infants treated with antibiotics for suspected early-onset neonatal sepsis.





Caesarean section, n (%) 62 (47.0) 46 (51.1) 0.54
PROM, n (%) 18 (13.6) 16 (18.2) 0.36
Positive maternal GBS status, n (%) 27 (23.3) 20 (26.7) 0.60
Product of multiple gestation, n (%) 7 (5.3) 6 (6.7) 0.67
Female gender, n (%) 63 (47.7) 47 (52.2) 0.51
Median gestational age, weeks (Q1-Q3) 39.1 (37.1–40.2) 39.2 (37.1–40.5) 0.52
Median birthweight, grams (Q1-Q3) 3'220 (2760–3660) 3'100 (2630–3540) 0.27
Median umbilical artery pH (Q1-Q3) 7.23 (7.17–7.29) 7.25 (7.15–7.30) 0.90
Median umbilical vein pH (Q1-Q3) 7.32 (7.27–7.36) 7.33 (7.28–7.36) 0.42
Median 1 min Apgar score (Q1-Q3) 8 (4–9) 8 (6–9) 0.41
Median 5 min Apgar score (Q1-Q3) 9 (7–10) 9 (8–9) 0.62
Median 10 min Apgar score (Q1-Q3) 9 (8–10) 9 (8–10) 0.72
GBS = group B streptococcus; PROM = premature rupture of membranes, Q1 = first quartile; Q3 = third quartile
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plemented repeated clinical evaluations, we observed a re-
duction of over 6 hours in the median time between birth
and the first dose of antibiotics in treated patients compared
with the period preceding the change in the protocol. Most
importantly, the impact of the change of protocol on short-
ening the time to initiate antibiotic treatment was even
stronger in patients with neonatal infection. Antibiotics
were started earlier in infants with a lower gestational age
and/or birthweight, and in infants born after PROM. Yet,
after adjustment for these variables, the change of protocol
was still associated with earlier antibiotic treatment. These
findings are clinically significant. Indeed, a delay in admin-
istration of antibiotics of more than one hour is associated
with an increased mortality in adults with sepsis [16, 17].
The majority of newborns who die from sepsis die during
the first 72 hours due to overwhelming infection, emphas-
ising the crucial importance of early antibiotic treatment [1,
18].
Despite the low positive predictive value of CBC and CRP,
it is tempting for clinicians to order these easily available
tests to decide whether or not to start antibiotics in asymp-
tomatic infants with risk factors for EOS [6–10]. This ap-
proach is supported by the 2012 guidelines of the American
Academy of Pediatrics who recommend performing a CBC
and measuring CRP between 6 and 12 hours postnatally
in asymptomatic infants born in the context of inadequate
GBS prophylaxis, PROM or chorioamnionitis [4]. This re-
commendation is based on data indicating that the informa-
tion provided by the diagnostic tests increases with postnat-
al age [6, 9]. However, the majority of infants who develop
EOS are symptomatic before 12 hours of life [12, 13, 19].
Therefore, a CBC and a CRP measurement at 6–12 hours
postnatally may not identify infants with EOS before de-
velopment of symptoms. Performing diagnostic tests in the
large population of infants with risk factors for EOS gen-
erates significant costs and leads to a number of painful
procedures [20]. In the present study, early detection and
prompt initiation of antibiotic treatment was achieved in in-
fants with neonatal infection by careful clinical observation
of newborns with risk factors, without performing adjunct
laboratory tests.
Reduction in the use of diagnostic tests in infants with risk
factors for EOS led to a slight but nonsignificant decrease
in the proportion of infants who received antibiotics. Over-
all, the proportion of infants who received intravenous anti-
biotics for suspected EOS was two-fold lower in our patient
population compared with previously reported data [7, 21].
No change in the rate of inappropriate antibiotic treatment
was observed between the two study periods. There was no
difference in the incidence of complications and outcome
of infants with neonatal infection between the two study
periods. The duration of antibiotic treatment was shorter
during Period 2, most likely due to an earlier discontinu-
ation of antibiotic treatment in noninfected infants during
Period 2 compared with Period 1. Following implement-
ation of the Protocol used during Period 2, we observed
a 91% reduction in the number of CRPs measured at our
maternity clinic, which indicates good adherence to the
protocol. The reduction in the number of CBCs was only
30%, due to the fact that most CBCs were obtained for the
workup of hyperbilirubinaemia.
The strengths of our study include the use of a clinical in-
formation system that allows reliable identification of pa-
tients and accurate determination of the time between birth
and the first dose of antibiotics, a simple design with the
use of clearly defined criteria to diagnose neonatal infec-
tion, and highly significant results. Our study has sever-
al limitations. First, it is an observational study. Although






Median time between birth and the first dose of antibiotics, hours (Q1-Q3) 10.7 (4.1–26.9) 4.5 (2.6–10.9) 0.002
Median duration of antibiotic treatment, hours (Q1-Q3) 77.5 (64.0–158.3) 64.2 (62.3–133.3) 0.001
Median duration of hospital stay, days (Q1-Q3) 7.0 (5.0–9.0) 6.0 (4.0–8.0) 0.77
Patients with neonatal infection, n (%) 36 (27.3) 16 (17.8) 0.70
Noninfected neonates, n (%) 96 (72.7) 74 (82.2) 0.10
Catecholamine treatment, n (%) 6 (4.5) 5 (5.6) 0.98
Mechanical ventilation, n (%) 13 (9.8) 8 (8.9) 0.81
Noninvasive ventilation, n (%) 57 (43.2) 49 (54.4) 0.81
Meningitis, n (%) 1 (0.76) 0 0.85
Mortality, n (%) 1 (0.76) 0 0.85
Any complication* 8 (6.1) 5 (5.6) 0.89
* Requirement for catecholamine treatment and/or mechanical ventilation, meningitis or death
Q1 = first quartile; Q3 = third quartile
Table 3: Uni- and multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) for the time between birth and the first dose of antibiotics according to the time
period, gestational age, birthweight and premature rupture of membranes (PROM).
Univariable analysis Multivariable analysis
Covariable Level HR 95% CI p-value HR 95% CI p-value
Time period 1 1 1
2 1.58 1.20–2.07 <0.001 1.56 1.17–2.07 0.002
Gestational age +1GA wk 0.91 0.84–0.97 0.005 0.92 0.84–1.01 0.089
Birthweight +1g 0.99 0.99–0.99 0.002 0.99 0.99–1.00 0.418
PROM No 1 1
Yes 1.41 0.98–2.06 0.065 1.33 0.91–1.93 0.136
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treatment strategies in general remained stable in our unit
during the whole study period, we cannot rule out that
some variations in clinical practice might have influenced
our results. Similar clinical characteristics of patients
treated for suspected EOS during the two study periods and
multivariable analysis of potential confounders reduce the
potential bias induced by the study design. Second, it is a
historically controlled study planned to assess the safety of
the protocol used during Period 2. Being part of a study
could have influenced the clinical assessment by residents.
Third, the majority of infants treated during Period 1 had a
first CBC and CRP measurement performed before 6 hours
of life. Obtaining CBCs and CRPs before 6 hours of life is
likely to increase the proportion of falsely reassuring res-
ults compared with later time points [6, 9]. During Period
2, deciding whether or not to start antibiotics on the basis
of clinical examination and risk factors alone lead to treat-
ment of 56% of patients with neonatal infection before 6
hours of life and 75% before 12 hours. There is no evidence
from clinical studies that performing a CBC and/or a CRP
at 6–12 hours would have led to earlier treatment. Another
limitation is the low incidence of culture-proven sepsis in
our patients (0.26‰ in our study vs 0.4‰–0.9‰ in recent
studies on term and late preterm infants [1, 22]). However,
culture-proven sepsis represents only a proportion of the
total cases of EOS [7, 10, 19]. Gestational age character-
istics and several aspects of perinatal care may have con-
tributed to a low incidence of culture-proven sepsis in our
population.
In conclusion, reduction in the use of diagnostic tests such
as CBC and CRP does not delay initiation of antibiotic
treatment in newborns with suspected EOS. On the con-
trary, it results in earlier treatment in infants with suspected
EOS and in infants with neonatal infection. The importance
of repeated clinical examination in infants with risk factors
for EOS should be emphasised.
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Figures (large format)
Figure 1
Kaplan-Meier estimates of the time between birth and the first dose of antibiotics in: (A) all infants treated for suspected early-onset neonatal
sepsis during Period 1 (full line, n = 132) and Period 2 (dotted line, n = 90), p <0.001; (B) infants with neonatal infection during Period 1 (full line,
n = 36) and Period 2 (dotted line, n = 16), p <0.001.
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